Porous silicon based intravitreal platform for dual-drug loading and controlled release towards synergistic therapy
| العنوان: | Porous silicon based intravitreal platform for dual-drug loading and controlled release towards synergistic therapy |
|---|---|
| المؤلفون: | Ying Xiao, William R. Freeman, Kristyn Huffman, Fangting Li, Lingyun Cheng, David Warther, Michael J. Sailor, Yuqin Wang |
| المصدر: | Drug Delivery Drug delivery, vol 25, iss 1 Drug Delivery, Vol 25, Iss 1, Pp 1537-1545 (2018) |
| بيانات النشر: | Informa UK Limited, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Male, intravitreal drug delivery, Anti-Inflammatory Agents, Pharmaceutical Science, 02 engineering and technology, Pharmacology, Drug Delivery Systems, 0302 clinical medicine, Antibiotics, Spectroscopy, Fourier Transform Infrared, Pharmacology & Pharmacy, Spectroscopy, media_common, Antibiotics, Antineoplastic, medicine.diagnostic_test, Dual-drug loading, Drug Synergism, Pharmacology and Pharmaceutical Sciences, General Medicine, 021001 nanoscience & nanotechnology, Antineoplastic, Controlled release, Microspheres, 3. Good health, porous silicon, Female, Rabbits, medicine.symptom, 0210 nano-technology, Porosity, Research Article, medicine.drug, Drug, Silicon, Combination therapy, Daunorubicin, media_common.quotation_subject, dexamethasone, Inflammation, 03 medical and health sciences, Refractory, medicine, Animals, Particle Size, Dexamethasone, business.industry, lcsh:RM1-950, Vitreous Body, lcsh:Therapeutics. Pharmacology, Fourier Transform Infrared, Delayed-Action Preparations, 030221 ophthalmology & optometry, controlled release, business, Electroretinography |
| الوصف: | The number of blind and low vision persons in the US is projected to increase to 5.68 million by 2020. The eye diseases causing loss of vision are life-long, chronic, and often need protracted presence of therapeutics at the disease site to keep the disease in remission. In addition, multiple pathologies participate in the disease process and a single therapy seems insufficient to bring the disease under control and prevent vision loss. This study demonstrates the use of porous silicon (pSi) particles sequentially loaded with daunorubicin (DNR) and dexamethasone (DEX) to create a synergistic intravitreally injectable dual-drug delivery system. DEX targets chronic inflammation while DNR inhibits excessive cell proliferation as well as suppresses hypoxia-inducible factor 1 to reduce scarring. This pSi-based delivery system releases therapeutic concentrations of DNR for 100 days and DEX for over 165 days after a single dose. This intravitreal dual-drug delivery system is also well tolerated after injection into the rabbit eye model, attested by ocular biomicroscopy, ocular tonometry, electroretinography, and histology. This novel dual-drug delivery system opens an attractive modality for combination therapy to manage refractory chorioretinal diseases and further preclinical studies are warranted to evaluate its efficacy. |
| وصف الملف: | application/pdf |
| تدمد: | 1521-0464 1071-7544 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86128ba8733d184bf38fd6db2b995943Test https://doi.org/10.1080/10717544.2018.1486474Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....86128ba8733d184bf38fd6db2b995943 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15210464 10717544 |
|---|